Skip Navigation


ToxSci Advance Access originally published online on January 6, 2009
Toxicological Sciences 2009 108(1):4-18; doi:10.1093/toxsci/kfn263
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/1/4    most recent
kfn263v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wells, P. G.
Right arrow Articles by Wong, A. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wells, P. G.
Right arrow Articles by Wong, A. W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Oxidative Stress in Developmental Origins of Disease: Teratogenesis, Neurodevelopmental Deficits, and Cancer

Peter G. Wells*,{dagger},1, Gordon P. McCallum*, Connie S. Chen*,2, Jeffrey T. Henderson*, Crystal J. J. Lee*, Julia Perstin*, Thomas J. Preston*,3, Michael J. Wiley{ddagger} and Andrea W. Wong*,4

* Faculty of Pharmacy {dagger} Departments of Pharmacology and Toxicology {ddagger} Surgery, University of Toronto, Toronto, Ontario, Canada

1 To whom correspondence should be addressed at Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, Canada M5S 3M2. Fax: (416) 267-7797. E-mail pg.wells{at}utoronto.ca.

Received May 23, 2008; accepted December 11, 2008


   Abstract

In the developing embryo and fetus, endogenous or xenobiotic-enhanced formation of reactive oxygen species (ROS) like hydroxyl radicals may adversely alter development by oxidatively damaging cellular lipids, proteins and DNA, and/or by altering signal transduction. The postnatal consequences may include an array of birth defects (teratogenesis), postnatal functional deficits, and diseases. In animal models, the adverse developmental consequences of in utero exposure to agents like thalidomide, methamphetamine, phenytoin, benzo[a]pyrene, and ionizing radiation can be modulated by altering pathways that control the embryonic ROS balance, including enzymes that bioactivate endogenous substrates and xenobiotics to free radical intermediates, antioxidative enzymes that detoxify ROS, and enzymes that repair oxidative DNA damage. ROS-mediated signaling via Ras, nuclear factor kappa B and related transducers also may contribute to altered development. Embryopathies can be reduced by free radical spin trapping agents and antioxidants, and enhanced by glutathione depletion. Further modulatory approaches to evaluate such mechanisms in vivo and/or in embryo culture have included the use of knockout mice, transgenic knock-ins and mutant deficient mice with altered enzyme activities, as well as antisense oligonucleotides, protein therapy with antioxidative enzymes, dietary depletion of essential cofactors and chemical enzyme inhibitors. In a few cases, measures anticipated to be protective have conversely enhanced the risk of adverse developmental outcomes, indicating the complexity of development and need for caution in testing therapeutic strategies in humans. A better understanding of the developmental effects of ROS may provide insights for risk assessment and the reduction of adverse postnatal consequences.

Key Words: teratogenesis; neurodevelopmental deficits; cancer; oxidative stress; reactive oxygen species; phenytoin; benzo[a]pyrene; methamphetamine; thalidomide; ionizing radiation.


2 Current address: Loewen, Ondaatje and McCutcheon Ltd., Toronto, Ontario, Canada.

3 Current address: Nucro-Technics, Scarborough, Ontario, Canada.

4 Current address: Cantox Health International, Mississauga, Ontario, Canada.

An earlier version of this review was presented as a keynote lecture at the 11th International Congress of Toxicology, Montreal, Quebec, July 2007. Proceedings, No. K3.0, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mol Hum ReprodHome page
D. G. Mottershead and A. J. Watson
Oocyte peptides as paracrine tools for ovarian stimulation and oocyte maturation
Mol. Hum. Reprod., December 1, 2009; 15(12): 789 - 794.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. J. Preston, J. T. Henderson, G. P. McCallum, and P. G. Wells
Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs
Mol. Cancer Ther., July 1, 2009; 8(7): 2015 - 2026.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.